Welcome to Pharma Disclosure

This website has been developed as a joint initiative between the European Federation of Pharmaceutical Industries and Associations (EFPIA) and VitalTransformation.com to highlight the industry’s new rules on disclosing financial relationships with doctors and healthcare organisations, follow progress in the implementation and to monitor compliance in the 33 countries involved in the initiative.

EFPIA’s’ Code on Disclosure of Transfers of Value from Pharmaceutical Companies to Healthcare Professionals and Healthcare Organisations’, agreed in July 2013, requires its members to disclose any direct payments or other forms of support.

Following unanimous backing by individual pharmaceutical companies, the code was adopted by national bodies at the end of 2013 and they are now preparing for its implementation in the 2015 calendar year.

Collaboration between the industry and healthcare professionals is an essential two-way street in which the industry gets clinical feedback that helps to shape the research and development of new medicines, whilst being a channel for companies to provide the essential expertise and insights about their drugs that clinicians require to deliver the highest quality treatment for patients.

Such interactions sit at the heart of health systems worldwide. However, EFPIA and its members recognise there is potential for conflicts of interest on both sides, requiring complete transparency about transfers of value from the industry to healthcare organisations including hospitals, clinics, universities and research institutions, and to individual clinical experts.

The move to introduce the new transparency code in Europe mirrors the introduction in the US of ‘Physician Financial Transparency Reports’ under the Sunshine Act (which is part of the Affordable care Act). Pharmaceutical companies in the US are required to submit the first reports by the end of March, with the centralised database run by the Centers for Medicare & Medicaid Services (CMS), which went live on September 30. In the US as in Europe, individuals and organisations will have the opportunity to check the reports before publication.

The pharmaceutical industry as a whole is committed to increasing transparency, reporting on an individual level all payments to medical professionals. It should be understood that the motivation is not to reduce support for healthcare systems, but to better align industry practices with the interests of patients.

While databases reporting transfers of value will operate at a national level, this website will provide a central repository, explaining how the system operates, monitoring progress and highlighting best practice.

EFPIA will also be organising and contributing to events to publicise the code, and we will report back here.

In addition to giving their backing to the code, individual member companies are taking specific initiatives, for example, changing the way in which sales representatives are remunerated, adjusting the ways in which they support medical conferences and opening up new channels for continuing professional education for doctors, and these will be showcased here.

EFPIA believes interactions between the pharmaceutical industry and healthcare professionals are overwhelmingly positive and have a profound influence on the quality of treatment and the continuing push for innovation.

However, we also recognise the need to modernise these relationships to maintain integrity and transparency, in an era when the level of collaboration between industry and healthcare is increasing in the interests of patients.